Q-omics provides the consensus-scored RPL37 profile across patient tissues and cancer cell-line models. RPL37 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL37 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RPL37 RNA expression shows 18,555 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KIRC, and THYM as cancer lineages where RPL37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL37 survival associations across molecular data types. RPL37 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL37 RNA expression–survival associations across cancer types. High RPL37 expression shows unfavorable associations in LIHC, KIRP, ACC and KICH, but favorable associations in LGG and UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL37 RNA expression.
This table summarizes RPL37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL37 shows higher tumor expression in KIRC, COAD, LIHC, KIRP, LUAD and HNSC. The KIRC box plot shows higher RPL37 RNA expression in tumor versus normal tissue (log2 FC = +1.161, t-test p < 0.001).
This table shows molecular features associated with RPL37 in patient tissues and cancer cell lines. In patient samples, RPL37 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
